Condition: Dementia · Sponsor: Woolsey Pharmaceuticals
Fasudil, a Rho kinase inhibitor, is believed to reduce wandering behaviors of elopement and getting lost by improving spatial memory and navigation through improvements in hippocampal blood flow. Fasudil is non-sedating. The aim of the study is to assess the effectiveness of oral fasudil in reducing wandering behaviors of elopement and/or getting lost in subjects with dementia. In addition, effects on wandering behaviors of excess movement and pacing, cognition, memory, neuropsychiatric symptomatology, caregiver/nursing staff burden, and the safety and tolerability of fasudil treatment will be assessed.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| New England Institute for Clinical Research | Stamford, Connecticut, United States | — |
| Accel Research Sites | Lakeland, Florida, United States | — |
| Lakes Research, LLC. | Miami Lakes, Florida, United States | — |
| Bio Behavioral Health | Toms River, New Jersey, United States | — |
| Albuquerque Neuroscience Inc. | Albuquerque, New Mexico, United States | — |
| Re:Cognition Health | Fairfax, Virginia, United States | — |
| Modbury Hospital | Modbury, South Australia, Australia | — |
| Barwon Geriatrics | Geelong, Victoria, Australia | — |
| GV Health | Shepparton, Victoria, Australia | — |
| Northeast Health Wangaratta | Wangaratta, Victoria, Australia | — |
| Neurodegenerative Disorders Research | West Perth, Western Australia, Australia | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04793659